EcoDrugPlus

Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 2

Ensembl ID : ENSEEUG00000015797
Gene Symbol: CACNG2
1 External references
262 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSEEUG00000000594
Gene Symbol: CACNA1D
1 External references
280 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSEEUG00000003927
Gene Symbol: CACNA1E
1 External references
295 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSEEUG00000009437
Gene Symbol: CACNA1F
1 External references
176 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSEEUG00000000891
Gene Symbol: CACNA1G
1 External references
198 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSEEUG00000011269
Gene Symbol: CNR1
4 External references
207 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSEEUG00000007147
Gene Symbol: CNR2
4 External references
196 Possible Orthologues:

Carbonic Anhydrase 13

Ensembl ID : ENSEEUG00000014581
Gene Symbol: CA13
1 External references
291 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSEEUG00000013266
Gene Symbol: CA14
1 External references
211 Possible Orthologues:

Carbonic Anhydrase 2

Ensembl ID : ENSEEUG00000007229
Gene Symbol: CA2
1 External references
285 Possible Orthologues:

Carbonic Anhydrase 3

Ensembl ID : ENSEEUG00000007144
Gene Symbol: CA3
1 External references
310 Possible Orthologues:

Carbonic Anhydrase 6

Ensembl ID : ENSEEUG00000005562
Gene Symbol: CA6
3 External references
227 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).